By Frank Prenesti
Date: Monday 01 Oct 2018
(Sharecast News) - AstraZeneca said it had agreed a $200m deal with Germany's Cheplapharm Arzneimittel for the European commercial rights to Atacand and Atacand Plus heart and hypertension treatments.
Sunday share tips: AstraZeneca, Genus, 'Dogs of ... | 30-Jul-2017 | ShareCast |
AstraZeneca co-develops treatment for Alzheimer'... | 09-Dec-2016 | ShareCast |
No recent information was found.
Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
Currency | UK Pounds |
Share Price | 10,992.00p |
Change Today | -128.00p |
% Change | -1.15 % |
52 Week High | 13,250.00 |
52 Week Low | 9,642.00 |
Volume | 31,315 |
Shares Issued | 1,264.16m |
Market Cap | £138,957m |
Strong Buy | 10 |
Buy | 13 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 0 |
Total | 28 |
Time | Volume / Share Price |
08:53 | 10 @ 10,992.00p |
08:53 | 31 @ 10,992.00p |
08:53 | 10 @ 10,994.00p |
08:53 | 72 @ 10,994.00p |
08:53 | 1 @ 10,996.00p |
You are here: research